drugset / Trial / NCT06315699
Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome
RandomizedCrossoverTriple-blindTreatment
Summary
This study focuses on therapeutic targets for cognitive, motor, and social impairments in Williams syndrome by reversing brain myelin defects caused by GTF2I. The primary objective of the study was to test and evaluate the initial efficacy and safety of Clomastine fumarate in the treatment of Williams syndrome.
Timeline
- Start
- 2024-03-20
- Primary completion
- 2025-03-02
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clemastine | Small molecule | 0.178 mg/kg | — |